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Maximizing the impact of microphysiological
systems with in vitro–in vivo translation
Murat Cirit *a and Cynthia L. Stokesb
Microphysiological systems (MPS) hold promise for improving therapeutic drug approval rates by providing
more physiological, human-based, in vitro assays for preclinical drug development activities compared to
traditional in vitro and animal models. Here, we first summarize why MPSs are needed in pharmaceutical
development, and examine how MPS technologies can be utilized to improve preclinical efforts. We then
provide the perspective that the full impact of MPS technologies will be realized only when robust ap-
proaches for in vitro–in vivo (MPS-to-human) translation are developed and utilized, and explain how the
burgeoning field of quantitative systems pharmacology (QSP) can fill that need.
1. Why MPSs are needed in
pharmaceutical development
The field of Microphysiological Systems (MPS)—also called
tissue chips or physiome-, organ-, or human-on-a-chip—is de-
veloping quickly, fueled by strong support from federal
sources, the pharmaceutical industry's continuing need for
more predictive preclinical models, and promising early re-
sults from academic laboratories. Functional MPSs
representing tissues from numerous organs including liver,
lung, gut, skin, muscle, bone, brain, and more have been
reported in the last decade.1–3 These engineered, biomimetic
constructs are typically micro- or meso-fluidic scale devices
that are designed to better emulate in vitro the biology of hu-
man tissues and organs by utilizing human cells, especially
primary or induced pluripotent stem cell (iPSC)-derived cells;
three-dimensional micro-architectures and biologically based
substrates and compatible materials; multiple cell co-culture;
long-term (weeks+) tissue functionality; and more physiologi-
cal mechanical and chemical cues. In a sign the field is ma-
turing, transferability to and reproducibility by second parties
are being systematically tested, e.g., via the Tissue Chip Test-
ing Centers in the US,4,5 and offerings of commercial MPS
products and services have begun.1
While basic research on biological mechanisms is already
benefiting, a major motivation for the field is the continuing
challenge of translating preclinical knowledge to human clin-
ical outcomes in the pharmaceutical industry. That approxi-
mately 9 of 10 drug candidates entering clinical trials fail to
gain approval is well-documented.6,7 Clearly, new approaches
to improve these outcomes are sorely needed.
Understanding why drug candidates fail and how other de-
velopments have impacted success rates can be instructive for
maximizing the impact of new technologies such as MPSs. An
analysis of the BioMedTracker database from 2003–2011 for
835 companies and 4451 drugs found that the root causes for
suspended programs at phase 3 were 54% efficacy, 9% safety,
18% commercial and 19% unknown, and at NDA/BLA (new
drug application/biologics license application) were 58% effi-
cacy, 31% safety, 8% commercial and 13% unknown.7 In a
separate analysis for 2011–2012 of data from Thomson
Reuters, Drugs of Today, Arrowsmith found that failures from
phase II through submission were attributed 56% to efficacy,
28% safety, 7% strategic, 5% commercial and 5% operations.6
More granularly, phase II failures were attributed to 59% effi-
cacy, 22% safety, 16% strategic, and 3% other, and phase III
and submission failures were attributed 52% to efficacy, 35%
safety and 13% other. With failure rates in phase I of ∼35%
(ref. 7) being presumably mainly from safety, cumulatively
from phase I to submission about 50% of all failures are from
safety. A majority of the most expensive failures (in phases II
and III), however, are associated with efficacy. Nonetheless, it
should be recognized that toxicity in early phases often limits
dosing levels in later phases, with subsequent failures then at-
tributed to lack of efficacy rather than toxicity. Regardless, a
significant need for improved prediction clearly remains on
both fronts. Interestingly, a substantial portion of failures in
phases II and III are attributed to strategy, financial, and com-
mercial reasons, so obtaining better information to rational-
ize decisions at the earliest stages could also reduce late, ex-
pensive program cancellations.
Despite the overall statistics, improvements in certain
areas have been made. The attrition from phase 1 entrance
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to regulatory submission due to pharmacokinetics (PK) and
bioavailability was reduced from about 40% in 1991 to less
than 10% in 2000, and below 1% in phases II and III by
2007–2011.6,8–10 Clearly, the concerted efforts in the 1990’s to
assess ADME/DMPK (absorption, distribution, metabolism,
excretion/drug metabolism and pharmacokinetics) much ear-
lier as part of the lead qualification process, coupled with
new technologies making that possible (e.g., combinatorial
chemistry and high throughput screening), markedly reduced
PK/bioavailability as a significant cause of clinical trial fail-
ure.11 More recently, the use of biomarkers for clinical trial
patient selection has demonstrably improved success rates:
drug development programs that used such biomarkers had
25.9% likelihood of approval from phase I to approval while
those that didn't had only 8.4% approval rates,12 with bene-
fits found at every phase transition. As patient selection bio-
markers are typically related to drug mechanism-of-action,
these data suggest that improving understanding of mecha-
nisms can be highly beneficial to clinical success, if utilized
in trial decision making.
These reasons of pharmaceutical success and failure pro-
vide guidance to where MPS technology might best be ap-
plied to impact translation of preclinical results to clinical
success. Given the current state of MPS technology—showing
promise but not fully demonstrated—our aims in this Per-
spective are to examine how MPS technologies could improve
preclinical-to-clinical translation, and to show how utilizing a
quantitative systems pharmacology (QSP) framework would
be highly beneficial in those efforts.
2. How MPS technologies may
improve preclinical drug discovery
efforts
MPS technologies provide new in vitro approaches, early in
the drug discovery and development process, to understand
disease mechanisms and progression and assess drug–biol-
ogy interactions in a more physiologically-relevant manner.
The advantages compared to traditional cell cultures and ani-
mal testing are numerous. The increased tissue complexity in
disease MPSs provides a more realistic assessment platform
than immortalized cell lines and two-dimensional monocul-
tures common to in vitro assays, and may suffice as alterna-
tives for animal models in some cases. The use of human cell
sources, including primary cells and iPSCs, also eliminates
the issue of cross-species specificity that often confounds re-
sults from animal models. MPSs or multi-MPS platforms pro-
vide new testbeds in early development for evaluating poten-
tial drug–drug interactions as well as dosing and dose–
response relationships of drug combinations for both efficacy
and toxicity purposes. Assessment of responses may be in the
form of measuring chemical entities via sampling of media
or tissue or in some MPSs via rapid, noninvasive measure-
ments such as electrical and mechanical outputs (e.g., neural
action potentials and muscular contractile activity13). MPS
models of disease have potential for discovery of response
biomarkers. Further, tissue or cell sourcing from multiple do-
nors could provide insights into patient variability and en-
able patient stratification regarding who will benefit most
from a therapy. Sourcing from human iPSCs provides addi-
tional advantages for disease modeling, such as monogenetic
disorders for studies of disease mechanism and drug re-
sponses, as well as generating the equivalent of a patient
population harboring the same mutation. Examples of MPSs
focused on disease biology include efforts to represent cancer
metastasis in liver,14,15 thrombosis in lung,16 chronic ob-
structive pulmonary disease in lung,17 Barth syndrome in
heart,18 diabetes in an islet-liver pair,19 non-alcoholic fatty
liver disease (NAFLD)20 and systemic inflammation in inter-
connected gut and liver MPSs.21 Complex diseases that in-
volve multiple organs, such as diabetes and metabolic syn-
drome, can now be modeled by platforms comprising
multiple interconnected, interacting MPSs. Within an MPS or
multi-MPS platforms, sourcing all cells from a single patient
or differentiated from a single iPSC source is desirable for
precision medicine applications. Although some therapeutic
areas have substantially better drug approval rates than
others, all have great room for improvement and so none are
particularly more or less valuable targets for MPS
development.6,8–10,12
The characteristics of MPSs that hold promise for efficacy
studies may also improve early in vitro assessment of adverse
effects. For example, immune-competent MPSs would enable
studies of the effect of immune cells on drug–biology interac-
tions. Inflammation is hypothesized to be a major cause of
idiosyncratic drug toxicity in humans22,23 and appropriately
designed immune-competent MPSs could enable much ear-
lier assessment than presently available. Additionally, numer-
ous MPSs are being designed to operate for weeks or months,
which could improve the in vitro assessment of chronic toxic-
ities. Evaluation of toxic response markers over time could
provide guidance for clinical patient monitoring. This prom-
ise notwithstanding, MPSs tend to be more operationally
complex and resource intensive to use than typical in vitro
toxicity screens, so the most realistic applications may be in
assessment of toxicities related to multi-cell or -organ interac-
tions that are difficult to detect with simpler but higher
throughput assays.
While failures due directly to PK and bioavailability have
been greatly reduced, drug safety and efficacy are directly re-
lated to dose, exposure, biotransformation to active metabo-
lites, and uptake at sites of action, so improved early evalua-
tion of PK and drug disposition can still impact preclinical-
to-clinical translation. For example, for drug metabolism
modes that utilize ubiquitously expressed enzymes instead of
CYP or UGT (which are adequately modeled in liver-derived
cultures),24,25 a grouping of MPSs representing liver, kidney,
gut, lung, heart, fat, etc., could be used to assess drug disap-
pearance in many tissues.26 Further, MPSs utilizing primary
human cell sources may enable more relevant assessment
than cell lines, for example, BBB or kidney MPSs27,28 utilizing
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primary or iPSC-derived cells compared to existing in vitro
models using MDCK-MDR1 or HK-2 cell lines, respectively.
An essential requirement for pharmacologic applications
of MPSs is the quantitative evaluation of drug behavior and
tissue responses with markers and endpoints as relevant to
the clinic as possible, and subsequent in vitro–in vivo transla-
tion of these findings to human. The utility of computational
models to design MPS technologies and analyze MPS data is
well-demonstrated,26,30–34 however, there is still a scientific
gap on how to correlate, extrapolate or otherwise translate
quantitative MPS data to human clinical outcomes. In the fol-
lowing sections, we describe how quantitative systems phar-
macology (QSP) could and should be utilized to fill that gap.
3. Quantitative systems pharmacology
(QSP) is coming of age
Despite MPSs better representing human physiology, some
level of post-experimental analysis is needed because MPSs
are still in vitro systems that lack true systemic blood flow,
waste removal, hormonal and immune systems, a micro-
biome, and many other defining in vivo contextual systems
and cues. While some measures from MPSs may scale easily
from in vitro to in vivo, for example based on relative cell
numbers, many have no direct analog in vivo and will require
more sophisticated analysis to determine meaning for the
in vivo context. We believe QSP is a powerful, integrative
framework for such interpretation and translation efforts
(Fig. 1).
QSP can be defined as the “quantitative analysis of the dy-
namic interactions between drug(s) and a biological system
that aims to understand the behavior of the system as a
whole, as opposed to the behavior of its individual constitu-
ents”.35 As such, QSP thinking goes beyond traditional
pharmacokinetic/pharmacodynamics (PKPD) modeling to
integrate more mechanistic information from a broader
range of sources, such as mechanistic in vitro data (e.g., from
MPSs), target characteristics, drug properties, in vivo data,
human physiology, genetic information, human pathology
and prior clinical data.36
The transition from standard PK models to
physiologically-based PK (PBPK) models is a major example
of moving towards “systems thinking,” by placing preclinical
data into a more complete human context. Use of PBPK
models in pharmaceutical development is increasing rap-
idly.37,38 Integrating PBPK modeling with mechanistic models
of relevant biology and PD will enable the interrogation of
mechanisms of action and response to drugs for diverse dos-
ing regimens, while accounting for interspecies, population,
and disease state differences.
Several examples demonstrate how QSP modeling can in-
corporate numerous data sources into a quantitative mecha-
nistic framework to test hypotheses, explore the relative im-
portance of uncertainties, and extend understanding to
multiple patient populations. While these examples do not
utilize data from MPSs, the possibility to do so is clear.
In one of the most far reaching, integrative QSP efforts
within the pharmaceutical industry to date, Kirouac et al. de-
veloped a mechanism-based model of the MAPK signaling
network in a BRAFV600-mutant colorectal cancer to investi-
gate the potential benefit of combining three oncology drugs
with targets on the same biochemical pathway.39 The QSP
model integrates information from multiple sources on mul-
tiple scales (cellular biochemistry, genetics, in vitro cell
growth, in vivo tumor kinetics in patients and xenograft
models, and clinical tumor responses). With it, they identi-
fied mechanisms of differential activity of MEK and ERK in-
hibitors as well as differential effects of supra-physiological
MEK activity on resistance to MEK, ERK, and RAF inhibitors.
They simulated combination dose–response matrices for the
three drugs to inform combination studies for multiple can-
cer indications, and identified alternate dosing regimens that
might have better tolerability. They report they are using the
results to strategize indications and drug combination regi-
mens for clinical trials.
An example of the success of a QSP framework for toxicity
applications is DILIsym®, a mathematical model for
Fig. 1 Quantitative systems pharmacology models of the biology and
pharmacology for specific applications can be used to translate in vitro
results from MPSs into the in vivo human context. QSP models are
initially developed based on an array of biological and (patho)
physiological data as well as information about target and drug
characteristics (upper right). Then, quantitative information derived
from MPS experimentation provides values or ranges of specific
parameters to the models (top). MPS results might relate specifically to
drug activity or might provide biology-specific parameters with which
to define virtual patient biology for simulations of drug activity derived
from other sources. Simulation and analysis using MPS inputs are then
possible to predict aspects of drug efficacy, toxicity, DMPK, etc., for
virtual patients (individuals, populations, subpopulations) accounting
for knowledge gained from MPSs (bottom).
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predicting drug induced liver injury (DILI) from mechanistic
in vitro toxicity assays such as those for bile acid transporter
inhibition, mitochondrial oxygen consumption rate and oxi-
dative stress.40 DILIsym® comprises multiple interacting sub-
models (e.g., reactive metabolite generation, immune re-
sponses, bile acid homeostasis) to simulate the effect of a
drug on the liver as a whole across multiple mechanisms of
toxicity. Important insights into risks and mechanisms of
DILI have been gained through its use regarding the toxicity
and relative DILI risk of multiple drugs, as well as insights
into species differences.41–43 DILIsym® is a particularly good
example of integrating experimental and modeling para-
digms, in that the toxicity assays provide quantitative metrics
and the model utilizes these as inputs to its mechanistic al-
gorithm to translate in vitro measurements into risk of hepa-
totoxicity in vivo.
Another example is a study used to extend the intravenous
application of Tamiflu to infants as young as 2 weeks, a pop-
ulation at increased risk of complications and death from in-
fluenza.44,45 Complementing the existing data on oral treat-
ment in children under 2 years and toxicology data in
newborn animals, an age-dependent PBPK model of the
prodrug and its metabolite in both monkey and human was
utilized to demonstrate that intravenous infusions of Tamiflu
would produce plasma profiles similar to oral doses and
thereby not have higher safety risks. This new analysis pro-
vided the basis for the US Food and Drug Administration to
forego requiring an additional toxicological study and to ap-
prove Tamiflu treatment of influenza in infants as young as 2
weeks.44
As these examples illustrate, QSP models that account for
human biology and (patho)physiology as well as drug charac-
teristics can provide actionable insights at multiple stages of
drug development. Other reviews and publications provide
additional examples.35,40,46–50
4. Maximizing MPS value through
QSP for in vitro–in vivo translation
While integration of QSP models with MPS-based research is
still nascent,51 early applications for MPS design and data
analysis have already demonstrated its value. The seminal
work on model-guided MPS design and data analysis was car-
ried out by Shuler et al.,30–32,52–54 who utilized PBPK models
to design multi-MPS platforms based on scaling blood resi-
dence times in organs, and to analyze mechanistic data on
drug toxicity studies with multi-MPS platforms. More re-
cently, mechanistic models of drug kinetics in single liver
and liver-gut MPS platforms have been shown to be more
useful than traditional PK models for estimating intrinsic
ADME parameters, probe mechanisms of LPS-induced in-
flammation, and evaluate inter-MPS communication on PK
processes.26,33 Multiple studies have demonstrated the criti-
cal nature of quantitative modeling for pharmacological ap-
plications of multi-MPS platforms, which are even more com-
plex than single MPSs.29,54 To address the difficult question
of appropriate scaling in MPS design51,55–57 and move scaling
from allometry to function-based, Maass et al.34 devised a
new, functional approach. Their mechanistic model-based,
multi-functional scaling method identifies physical design
and operational parameters for single and multi-MPS plat-
forms based on initial specification of required biological
function. A proof-of-concept study focused on drug exposure
demonstrated significant differences in MPS design based on
this functional scaling approach compared to allometric scal-
ing approaches.
With the benefits of model-based MPS design and data
analysis demonstrated, it is time to extend MPS-QSP integra-
tion to the translation of MPS-derived data (Fig. 1). QSP
models are helpful whenever multiple functions operate si-
multaneously and/or are nonlinearly related, which is the
case in most of human (patho)physiology and is necessarily
repeated in MPSs that strive to recapitulate that. The exam-
ples in section 3 illustrate the power of integrative, mechanis-
tic models to translate in vitro experimental data to humans,
in the context of known human physiology, drug and target
properties, and other available knowledge. A seminal applica-
tion of QSP for in vitro–in vivo translation of MPS data was
the study of Tsamandouras et al.25 assessing population vari-
ability in hepatic drug metabolism using the liver MPS. In
this, a population PBPK model was developed for lidocaine
to extrapolate in vitro MPS data to the observed PK variability
in vivo.
To understand how QSP models could be used to interpret
MPS-generated data, a few thought experiments are useful. In
the DILI study in section 3, for example, MPSs that embody
biological functions or context important for evaluation of
specific toxicity mechanisms, and better than existing in vitro
assays, could provide inputs to DILIsym® or similar QSP
models for hepatotoxicity predictions. In the study by Kirouac
of the MAPK pathway for cancer therapy,39 a possible use
would be MPSs representing tumor-organ systems to provide
alternate (human) data to xenograft models on individual
drug dose–responses as inputs for the model investigations
of drug combinations. Conversely, such MPSs could provide
human-based in vitro testbeds for validating the dose–re-
sponse matrices of drug combinations that were predicted
prior to or instead of further animal studies.
This points out that a key area of MPS-QSP benefit is in
the evaluation and understanding of multi-drug situations,
related to either efficacy39,46 or the complications of drug–
drug interactions. An example of the latter is Long et al., in
which the effect of tocilizumab, an IL-6 receptor antagonist,
on simvastatin PK in rheumatoid arthritis patients58 could be
recapitulated over two weeks in an immune-competent liver
MPS under inflammatory conditions.59 Further experimenta-
tion to investigate stimulus–response relationships for both
drugs and inflammatory levels would benefit from a QSP
model encompassing mechanisms of inflammatory modula-
tion of drug metabolism as well as tocilizumab and simva-
statin PK to extrapolate the in vitro findings to the in vivo pa-
tient setting.
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Numerous other applications in which QSP translation
will be needed to maximally utilize MPS-based data can be
envisioned. A promising use of MPSs is to understand tis-
sue site of action PD and toxicodynamics as well as evalu-
ate potential efficacy and toxicity biomarkers. Tissue accu-
mulation and therapeutic effects could be quantitatively
evaluated in MPSs, and QSP models could extrapolate to
in vivo organ accumulation and predict PK/PD and
toxicokinetic/toxicodynamic relationships at sites of action.
Given that patient selection biomarkers result in a more
than three-fold increase in likelihood of drug approval,12
disease MPSs could provide a major new tool for discovery
and/or evaluation of disease biomarkers. In concert, QSP
models could put such information in human context to
understand relationships to disease mechanism and drug
mechanism-of-action, possibly helping speed new bio-
markers into the clinic. Further, MPS-QSP studies can be
used to evaluate the kinetics of biomarkers, which could
then inform the timing of biomarker sampling in clinical
trials.
MPS technologies have the potential to provide an experi-
mental framework to accurately assess drug responses for pa-
tient sub-populations and even individuals, and thus, integra-
tive MPS-QSP approaches should better enable precision and
personalized medicine applications to find proper treatment
options for individuals. For example, adverse drug effects for
populations with renal or hepatic impairment can be experi-
mentally evaluated in appropriate MPSs and then, dose ad-
justments for these patients can be calculated with QSP
models. Moreover, therapeutic windows of combination treat-
ments could be assessed using MPS data-driven QSP models.
MPSs from various organ systems can provide testbeds for
preclinical evaluation of therapeutic and adverse effects of
combination therapies, while QSP models adjust the dosing
regimen for the clinic.
A final hurdle for realizing the potential of MPS technolo-
gies, QSP models, and their integration for drug development
is the acceptance of information derived from them by regu-
latory bodies.60 It is promising that results from computa-
tional models, including mechanistic QSP models, are in-
creasingly part of successful regulatory filings.46,47,61,62
Modeling contributions in recent years in INDs, NDAs and
BLAs include estimating first in human dose,63 predicting
drug–drug interactions,64,65 extensions of drug PK/PD to spe-
cial patient populations (e.g., hepatic and renal impairment,
and pediatrics38,63), and understanding disease progression
as well as dose–exposure–response relationships,46,66 among
other things. Favorably, a major goal of the US Food and
Drug Administration in 2018–2022 is to update its regulatory
science and review expertise to facilitate the development
and application of “model-informed drug development”.67
While use of MPS technologies to directly influence regula-
tory decisions is not yet demonstrated, it is our expectation
that mechanistic systems methods, involving both MPSs and
QSP models, will continue to gain acceptance for regulatory
decisions.
5. Conclusion
In conclusion, the perspective that MPS technologies hold
great promise for impacting preclinical-to-clinical translation
in the pharmaceutical arena is supported from multiple di-
rections: an understanding of the unaddressed needs in the
drug R&D pipeline; the demonstration that MPSs better reca-
pitulate human physiology than more traditional in vitro
models; recognition of the value of mechanistic QSP models
within biomedical and pharmaceutical R&D for integrating
and interpreting data from MPSs alongside other diverse
sources; and the support from regulatory agencies to include
and accept computational modeling in support of regulatory
applications. The MPS field will arguably have its greatest im-
pact going forward by utilizing quantitative model-based ap-
proaches, i.e., quantitative systems pharmacology, for MPS
design, data analysis and in vitro–in vivo translation.
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